A new treatment from Indianapolis-based Eli Lilly and Co. (NYSE: LLY) is now available in the United States. The drugmaker says Taltz is available by prescription to treat moderate-to-severe plaque psoriasis.
The U.S. Food and Drug Administration approved Taltz in March. The treatment showed positive results for patients with plaque psoriasis in three studies. The company is also offering support programs to make sure eligible patients have access to the treatment.
National Psoriasis Foundation President Randy Beranek says the availability of treatments like Taltz is "vitally important" for patients affected by the condition. In a release, he said, "The effects of psoriasis can vary among patients and what works for one patient may not work for another. We are happy to see more options available so patients can continue treating this very difficult disease."
Last month, Lilly reported first quarter net income of $440.1 million, compared to $529.5 million during the same quarter the previous year. Despite the dip, Chief Executive Officer John Lechleiter said the results reflected "substantial progress" in the launch of several high-profile products.